Inferra AIResearch Tools

Inferra AI / Company / RIGL

Rigel Pharmaceuticals Inc.

RIGL · Health Care

Last earnings Aug 4, 2026

Key results

Revenuequarter

76%

In the second quarter, we grew net product sales by 76% year-over-year, generated $59.6 million in net income and increased our cash balance to $108.4 million.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Net incomequarter

$59.6 million

In the second quarter, we grew net product sales by 76% year-over-year, generated $59.6 million in net income and increased our cash balance to $108.4 million.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

As a result of the notification, Rigel recognized $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability in the second quarter.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Contract revenuequarter

$40.0 million

Contract revenues from collaborations primarily consisted of $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability related to the agreement with Lilly for the development and commercialization of ocadusertib, $2.0 million of revenue from Grifols S.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

(Grifols) related to delivery of drug supplies and earned royalties, $0.4 million of revenue from Kissei related to the delivery of drug supplies, and $0.2 million of revenue from Medison Pharma (Medison) related to delivery of drug supplies and earned royalties.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Rigel reported net income of $59.6 million, or $3.33 basic and $3.28 diluted per share, compared to a net loss of $1.0 million, or $0.06 basic and diluted per share, for the same period of 2024.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Contract revenues from collaborations primarily consisted of $40.0 million in non-cash revenue resulting from the release of the remaining cost share liability related to the agreement with Lilly for the development and commercialization of ocadusertib, $6.7 million of revenue from Grifols related to delivery of drug supplies and earned royalties, $5.1 million of revenue from Kissei related to a milestone payment and delivery of drug supplies and $0.6 million of revenue from Medison related to delivery of drug supplies and earned royalties.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Rigel reported net income of $71.1 million, or $3.98 basic and $3.91 diluted per share, compared to a net loss of $9.3 million, or $0.53 basic and diluted per share, for the same period of 2024.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The above total revenues and contract revenues from collaborations are inclusive of $40 million in non-cash contract revenue related to Rigel’s agreement with Lilly.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

AI analysis

Q2 2025 · reported Aug 5, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Net income · Q2 2025
$59.6M
EX-99 · Aug 5, 2025
Contract revenue · Q2 2025
$40.0M
EX-99 · Aug 5, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
Revenue76%——
Net income$59.6 million——
Contract revenue$40.0 million——

EX-99 · Aug 5, 2025

Guidance · company-stated

Total revenue$280 million
sales

“of $210 to $220 million”

net income

“are inclusive of $40 million”

Guidance stated in the release's Outlook: table; no direction stated — figures as stated in the table.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Dividend4.1 %

We finance our operations primarily through sales of our products, and contract payments under our collaboration agreements, as well as through equity securities and debt financing.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

(Kissei) announced that its licensing partner, JW Pharmaceutical Corporation, commercially launched TAVALISSE in South Korea in early July

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Total revenue: “Total revenue of approximately $270 to $280 million”

sales: “sales of $210 to $220 million”

net income: “net income are inclusive of $40 million”

Total revenue (“Outlook:”)
“Total revenue of approximately $270 to $280 million”

sales (“Outlook:”)
“sales of $210 to $220 million”

net income (“Outlook:”)
“net income are inclusive of $40 million”

Guidance stated in the release's Outlook: table; no direction stated — figures as stated in the table.

Capital allocation

We finance our operations primarily through sales of our products, and contract payments under our collaboration agreements, as well as through equity securities and debt financing.

SEC original ↗Rigel Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 4, 2026

Based on our current operating plan, we believe that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Form 10-Q.

SEC original ↗Rigel Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 4, 2026

The following table summarizes the weighted-average assumptions relating to stock options granted during the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Risk-free interest rate * 4.1 % 3.8 % 4.3 % Expected term (in years) * 6.0 5.3 6.5 Dividend yield * 0.0 % 0.0 % 0.0 % Expected volatility * 90.5 % 90.5 % 88.6 % ______________________________________________________________________ * No stock options granted during the period.

SEC original ↗Rigel Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 4, 2026

Such share withholdings are treated as share repurchases for accounting purposes and are reflected as a reduction to additional paid-in capital.

SEC original ↗Rigel Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 4, 2026

Strategy & priorities

(Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE ® (fostamatinib disodium hexahydrate), GAVRETO ® (pralsetinib) and REZLIDHIA ® (olutasidenib), and recent business progress.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

“Our strategic and disciplined approach to building our business has generated another strong quarter for the company.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Later this year, we plan to share updated data from that study and initiate the dose expansion part of the study.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The company expects to share updated data from the study later this year and plans to initiate the dose expansion part of the study in the second half of this year.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

We focus on products that address signaling pathways that are critical to disease mechanisms.

SEC original ↗Rigel Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 4, 2026

Risks & headwinds

Instead, they are based on Rigel’s current beliefs, expectations, and assumptions and hence they inherently involve significant risks, uncertainties and changes in circumstances that are difficult to predict and many of which are outside of our control.

SEC original ↗Rigel Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 47 Item 1A.

SEC original ↗Rigel Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 4, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

31 documents

Earnings releases

9 documents

Presentations

0 documents

No presentations for Rigel Pharmaceuticals Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Rigel Pharmaceuticals Inc. are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Rigel Pharmaceuticals Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.